TP53 and glioblastoma: Preliminary studies also confirmed the presence of a synergic antiproliferative activity in GBM cell lines after cotreatment with the novel mTOR/AKT inhibitor FC85 and the MDM2/p53 blocker ISA27 (Daniele et al., 2015).